Advancing Gene Therapy for Ocular Diseases: Lunar Phase 2 Trial Design and Clinical Significance | Laurent Fischer, CEO, Adverum Biotechnologies Inc . 00:10:00
The discussion focuses on the Lunar Phase 2 trial of a gene therapy program targeting ocular diseases. It explores trial design, dosing strategies, and potential clinical impact, emphasizing the importance of stabilizing retinal fluid levels to preserve long-term vision and reduce treatment burden for patients. Case studies are presented to illustrate the benefits of steady-state therapeutic production.
